PKCδ silencing alleviates saturated fatty acid induced ER stress by enhancing SERCA activity

Biosci Rep. 2017 Nov 23;37(6):BSR20170869. doi: 10.1042/BSR20170869. Print 2017 Dec 22.

Abstract

Protein kinase C δ (PKCδ) plays an important role in nonalcoholic fatty liver disease (NAFLD), however, the mechanism remains unknown. The present study explored the role of PKCδ in NAFLD development and investigated the relationships between PKCδ, calcium homeostasis, and endoplasmic reticulum (ER) stress (ERS). Hepatic steatosis cell model was induced by palmitic acid (PA) in L02 cells. Lipid accretion was evaluated using Oil Red O staining and a triglyceride (TG) detection kit. PKCδ was down-regulated by siRNA. RT-PCR and Western blotting were used to detect the expression of ERS markers. The fluorescence of Ca2+ influx was recorded using confocal microscopy. Sarco-ER Ca2+-ATPase (SERCA) activity was measured by ultramicro-ATP enzyme test kit. PA treatment induced lipid accretion in L02 cells, destroyed the ER structure, and increased PKCδ activation in a time-dependent manner. Further, PA treatment significantly increased the expression of ERS markers, Ig heavy chain binding protein (Bip), and homologous proteins of CCAAT-enhancer binding proteins (CHOP). PKCδ silencing down-regulated Bip and CHOP expression, indicating a successful alleviation of ERS. The increased calcium storage induced by PA stimulation was significantly decreased in L02 cells treated with PKCδ siRNA compared with the negative control. Moreover, diminished SERCA activity caused by PA was recovered in PKCδ siRNA transfected cells. To the best of our knowledge, this is the first report demonstrating that the inhibition of PKCδ alleviates ERS by enhancing SERCA activity and stabilizing calcium homeostasis.

Keywords: ERS; NAFLD; PKCδ; SERCA; calcium homeostasis.

MeSH terms

  • Biomarkers / analysis
  • Biomarkers / metabolism
  • Calcium / analysis
  • Calcium / metabolism*
  • Cell Line
  • Endoplasmic Reticulum Stress* / drug effects
  • Fatty Acids / analysis
  • Fatty Acids / metabolism*
  • Hepatocytes / drug effects
  • Homeostasis*
  • Humans
  • Non-alcoholic Fatty Liver Disease / chemically induced
  • Non-alcoholic Fatty Liver Disease / enzymology*
  • Palmitic Acid / pharmacology
  • Protein Kinase C-delta / genetics
  • Protein Kinase C-delta / metabolism*
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / analysis
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism*

Substances

  • Biomarkers
  • Fatty Acids
  • RNA, Small Interfering
  • Palmitic Acid
  • Protein Kinase C-delta
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Calcium